Lipocine Valuation
Is LPCN undervalued compared to its fair value, analyst forecasts and its price relative to the market?
Valuation Score
1/6Valuation Score 1/6
Price-To-Earnings vs Peers
Price-To-Earnings vs Industry
Price-To-Earnings vs Fair Ratio
Below Fair Value
Significantly Below Fair Value
Analyst Forecast
Key Valuation Metric
Which metric is best to use when looking at relative valuation for LPCN?
Other financial metrics that can be useful for relative valuation.
| What is LPCN's n/a Ratio? | |
|---|---|
| n/a Ratio | 0x |
| n/a | n/a |
| Market Cap | US$46.91m |
| Key Statistics | |
|---|---|
| Enterprise Value/Revenue | 0.8x |
| Enterprise Value/EBITDA | 4x |
| PEG Ratio | 1.1x |
Price to Earnings Ratio vs Peers
How does LPCN's PE Ratio compare to its peers?
| Company | PE | Estimated Growth | Market Cap |
|---|---|---|---|
| Peer Average | 4.7x | ||
SHWZ Medicine Man Technologies | 8.6x | n/a | US$78.1m |
PRPH ProPhase Labs | 4.4x | 43.6% | US$137.9m |
ELTP Elite Pharmaceuticals | 5.2x | n/a | US$34.2m |
GNRS Greenrose Holding | 0.7x | n/a | US$8.8m |
LPCN Lipocine | 11.5x | 10.6% | US$46.9m |
Price-To-Earnings vs Peers: LPCN is expensive based on its Price-To-Earnings Ratio (11.5x) compared to the peer average (4.7x).
Price to Earnings Ratio vs Industry
How does LPCN's PE Ratio compare vs other companies in the US Pharmaceuticals Industry?
Price to Earnings Ratio vs Fair Ratio
What is LPCN's PE Ratio compared to its Fair PE Ratio? This is the expected PE Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.
| Fair Ratio | |
|---|---|
| Current PE Ratio | 11.5x |
| Fair PE Ratio | 10.8x |
Price-To-Earnings vs Fair Ratio: LPCN is expensive based on its Price-To-Earnings Ratio (11.5x) compared to the estimated Fair Price-To-Earnings Ratio (10.8x).
Share Price vs Fair Value
What is the Fair Price of LPCN when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.
Below Fair Value: Insufficient data to calculate LPCN's fair value for valuation analysis.
Significantly Below Fair Value: Insufficient data to calculate LPCN's fair value for valuation analysis.
Analyst Price Targets
What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?
| Date | Share Price | Average 1Y Price Target | Dispersion | High | Low | 1Y Actual price | Analysts |
|---|---|---|---|---|---|---|---|
| Current | US$0.52 | US$3.83 +636.5% | 37.4% | US$5.50 | US$2.00 | n/a | 3 |
| Jan ’24 | US$0.40 | US$3.83 +863.6% | 37.4% | US$5.50 | US$2.00 | n/a | 3 |
| Dec ’23 | US$0.46 | US$3.83 +739.5% | 37.4% | US$5.50 | US$2.00 | n/a | 3 |
| Nov ’23 | US$0.41 | US$3.33 +720.2% | 46.4% | US$5.50 | US$2.00 | n/a | 3 |
| Oct ’23 | US$0.45 | US$3.33 +640.7% | 46.4% | US$5.50 | US$2.00 | n/a | 3 |
| Sep ’23 | US$0.58 | US$3.33 +472.0% | 46.4% | US$5.50 | US$2.00 | n/a | 3 |
| Aug ’23 | US$0.79 | US$3.67 +365.8% | 35.8% | US$5.50 | US$2.50 | n/a | 3 |
| Jul ’23 | US$0.80 | US$3.67 +358.3% | 35.8% | US$5.50 | US$2.50 | n/a | 3 |
| Jun ’23 | US$0.84 | US$3.67 +334.2% | 35.8% | US$5.50 | US$2.50 | n/a | 3 |
| May ’23 | US$0.88 | US$3.83 +334.7% | 40.3% | US$6.00 | US$2.50 | n/a | 3 |
| Apr ’23 | US$1.34 | US$3.83 +186.1% | 40.3% | US$6.00 | US$2.50 | n/a | 3 |
| Mar ’23 | US$1.27 | US$3.83 +201.8% | 40.3% | US$6.00 | US$2.50 | n/a | 3 |
| Feb ’23 | US$1.04 | US$3.75 +260.6% | 35.9% | US$6.00 | US$2.50 | US$0.52 | 4 |
| Jan ’23 | US$0.99 | US$3.75 +278.4% | 35.9% | US$6.00 | US$2.50 | US$0.40 | 4 |
| Dec ’22 | US$1.02 | US$3.75 +267.6% | 35.9% | US$6.00 | US$2.50 | US$0.46 | 4 |
| Nov ’22 | US$1.06 | US$4.75 +348.1% | 64.2% | US$10.00 | US$2.50 | US$0.41 | 4 |
| Oct ’22 | US$1.06 | US$4.75 +348.1% | 64.2% | US$10.00 | US$2.50 | US$0.45 | 4 |
| Sep ’22 | US$1.31 | US$4.75 +262.6% | 64.2% | US$10.00 | US$2.50 | US$0.58 | 4 |
| Aug ’22 | US$1.32 | US$4.50 +240.9% | 70.7% | US$10.00 | US$2.50 | US$0.79 | 4 |
| Jul ’22 | US$1.40 | US$4.50 +221.4% | 70.7% | US$10.00 | US$2.50 | US$0.80 | 4 |
| Jun ’22 | US$1.22 | US$5.00 +309.8% | 70.7% | US$10.00 | US$2.50 | US$0.84 | 3 |
| May ’22 | US$1.41 | US$5.33 +278.3% | 61.9% | US$10.00 | US$3.00 | US$0.88 | 3 |
| Apr ’22 | US$1.55 | US$5.33 +244.1% | 61.9% | US$10.00 | US$3.00 | US$1.34 | 3 |
| Mar ’22 | US$1.55 | US$5.33 +244.1% | 61.9% | US$10.00 | US$3.00 | US$1.27 | 3 |
| Feb ’22 | US$1.71 | US$5.33 +211.9% | 61.9% | US$10.00 | US$3.00 | US$1.04 | 3 |
Analyst Forecast: Target price is more than 20% higher than the current share price, but analysts are not within a statistically confident range of agreement.